[Retracted] Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with EGFR-Mutated Non-Small-Cell Lung Cancer Regardless of Cerebrospinal Fluid T790M Mutational Status

Table 3

Univariate and multivariate analyses of OS from LM diagnosis.

Variables	n	Univariate analysis		Multivariate analysis
		HR (95% CI)	value	HR (95% CI)	value
Age, year
≤60	38	1.00	—	—	—
>60	40	0.85 (0.50–1.42)	0.525	—	—
Sex
Male	37	1.00	—	—	—
Female	41	0.95 (0.56–1.61)	0.859	—	—
Smoking
No	58	1.00	—	—	—
Yes	20	1.58 (0.85–2.96)	0.147	—	—
ECOG PS
0–2	49	1.00	—	1.00	—
≥3	29	3.95 (2.19–7.10)	≤0.001	3.22 (1.74–5.95)	≤0.001
Concurrent BM
No	38	1.00	—	—	—
Yes	33	1.07 (0.62–1.85)	0.807	—	—
Initial EGFR mutation
19DEL	42	1.00	—	—	—
21L8585R	33	1.06 (0.63–1.80)	0.823	—	—
Other	3	1.16 (0.56–2.40)	0.685	—	—
EGFR T790M mutation
Present	28	1.00	—	—	—
Absent	38	1.60 (0.89–2.90)	0.118	—	—
CSF pressure, mmH2O
≤180	25	1.00	—	—	—
>180	49	0.94 (0.53–1.65)	0.828	—	—
CSF protein, mg/dl
≤50	23	1.00	—	—	—
>50	44	0.99 (0.53–1.87)	0.987	—	—
CSF glucose, mmol/L
≥2.5	25	1.00	—	—	—
<2.5	43	1.08 (0.60–1.94)	0.808	—	—
Cytotoxic chemotherapy
No	35	1.00	—	—	—
Yes	40	0.87 (0.50–1.51)	0.625	—	—
IT chemotherapy
No	59	1.00	—	—	—
Yes	14	0.63 (0.30–1.34)	0.227	—	—
WBRT
No	63	1.00	—	1.00	—
Yes	13	0.45 (0.23–0.96)	0.038	0.77 (0.34–1.75)	0.539
VPS insertion
No	66	1.00	—	—	—
Yes	10	0.79 (0.39–1.58)	0.498	—	—
Osimertinib treatment
No	34	1.00	—	1.00	—
Yes	44	0.59 (0.45–0.78)	≤0.001	0.65 (0.49–0.87)	0.004

Note. HR: hazard ratio, CI: confidence interval, ECOG PS: Eastern Cooperative Oncology Group performance status, BM: brain metastases, IT: intrathecal, WBRT: whole-brain radiation therapy, and VPS: ventriculoperitoneal shunt.